Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33

Virology Journal

Volumn 3, Issue , 2006, Pages

  Roth, Stefanie D ^a   Sapp, Martin ^a,b   Streeck, Rolf E ^a   Selinka, Hans Christoph ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; HUMAN PAPILLOMAVIRUS TYPE 33; MUTAGENESIS; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; VIRUS CAPSID; VIRUS INFECTION;

ANTIBODIES, VIRAL; CAPSID PROTEINS; CELL LINE; COMPLEMENTARITY DETERMINING REGIONS; EPITOPES; HUMANS; MODELS, MOLECULAR; NEUTRALIZATION TESTS; PAPILLOMAVIRIDAE; PROTEIN CONFORMATION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 33; MIRIDAE; PAPILLOMAVIRIDAE;

EID: 33749995777     PISSN: 1743422X     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-3-83     Document Type: Article

References (41)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
2. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ: Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types. Obstet Gynecol 1992, 79:328-337.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
4. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347:1645-1651.
5. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, de Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G: Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 2004, 364:1757-1765.
6. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005, 6:271-278.
7. Volpers C, Schirmacher P, Streeck RE, Sapp M: Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 1994, 200:504-512.
8. Rose RC, Bonnez W, Reichman RC, Garcea RL: Expression of human papillomavirus type 11 L1 protein in insect cells: In vivo and in vitro assembly of virus-like particles. J Virol 1993, 67:1936-1944.
9. Hagensee ME, Yaegashi N, Galloway DA: Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993, 67:315-322.
10. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89:12180-12184.
11. Roden RB, Greenstone HL, Kirnbauer R, Booy FP, Jessie J, Lowy DR, Schiller JT: In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol 1996, 70:5875-5883.
12. Unckell F, Streeck RE, Sapp M: Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol 1997, 71:2934-2939.
13. Pastrana DV, Buck CB, Y Pang YY, Thompson CD, Castle PE, FitzGerald PC, Kruger Kjaer S, Lowy DR, Schiller JT: Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321:205-216.
14. Christensen ND, Reed CA, Cladel NM, Hall K, Leiserowitz GS: Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 1996, 224:477-486.
15. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M: Human papillomavirus infection requires cell surface heparan sulfate. J Virol 2001, 75:1565-1570.
16. Combita AL, Touzé A, Bousarghin L, Christensen ND, Coursaget P: Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002, 76:6480-6486.
17. Chen XS, Garcea RL, Goldberg I, Casini G, Harrison SC: Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000, 5:557-567.
18. Roden RB, Armstrong A, Haderer P, Christensen ND, Hubbert NL, Lowy DR, Schiller JT, Kirnbauer R: Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol 1997, 71:6247-6252.
19. Christensen ND, Cladel NM, Reed CA, Budgeon LR, Embers ME, Skulsky DM, McClements WL, Ludmerer SW, Jansen KU: Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 2001, 291:324-334.
20. Carter JJ, Wipf GC, Benki SF, Christensen ND, Galloway DA: Identification of a human papillomavirus type 16-specific epitope on the c-terminal arm of the major capsid protein L1. J Virol 2003, 77:11625-11632.
21. Fleury MJ, Touzé A, Alvarez E, Carpentier G, Clavel C, Vautherot JF, Coursaget P: Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol 2006, 151:1511-1523.
22. Rose RC, White WI, Li M, Suzich JA, Lane C, Garcea RL: Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol 1998, 72:6151-6154.
23. Fligge C, Schafer F, Selinka H-C, Sapp C, Sapp M: DNA-induced structural changes in the papillomavirus capsid. J Virol 2001, 75:7727-7731.
24. Buck CB, Pastrana DV, Lowy DR, Schiller JT: Efficient intracellular assembly of papillomaviral vectors. J Virol 2004, 78:751-757.
25. Ludmerer SW, Benincasa D, Mark GE, Christensen ND: A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope. J Virol 1997, 71:3834-3839.
26. White WI, Wilson SD, Palmer-Hill FJ, Woods RM, Ghim SJ, Hewitt LA, Goldman DM, Burke SJ, Jenson AB, Koenig S, Suzich JA: Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 1999, 73:4882-4889.
27. McClements WL, Wang XM, Ling JC, Skulsky DM, Christensen ND, Jansen KU, Ludmerer SW: A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology 2001, 289:262-268.
28. Carter JJ, Wipf GC, Madeleine MM, Schwartz SM, Koutsky LA, Galloway DA: Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 2006, 80:4664-4672.
29. Selinka H-C, Giroglou T, Nowak T, Christensen ND, Sapp M: Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol 2003, 77:12961-12967.
30. Orozco JJ, Carter JJ, Koutsky LA, Galloway DA: Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 L1 capsomers. J Virol 2005, 79:9503-9514.
31. Moss B, Elroy-Stein O, Mizukami T, Alexander WA, Fuerst TR: New mammalian expression vectors. Nature 1990, 348:91-92.
32. Sapp M, Kraus U, Volpers C, Snijders PJ, Walboomers JM, Streeck RE: Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein. J Gen Virol 1994, 75:3375-3383.
33. Bergsdorf C, Beyer C, Umansky V, Werr M, Sapp M: Highly efficient transport of carboxyfluorescein diacetate succinimidyl ester into Cos7 cells using human papillomavirus-like particles. FEBS Lett 2003, 536:120-124.
34. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG: The ClustalX windows interface: flexible strategies for multiple sequence alignmend aided by quality analysis tools. Nucl Acids Res 1997, 24:4876-4882.
35. Leder C, Kleinschmidt JA, Wiethe C, Muller M: Enhancement of capsid gene expression: Preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes. J Virol 2001, 75:9201-9209.
36. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR: Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989, 77:51-59.
37. An Y, Ji J, Wu W, Lv A, Huang R, Wei Y: A rapid and efficient method for multiple-site mutagenesis with a modified overlap extension PCR. Appl Microbiol Biotechnol 2005, 68:774-778.
38. Sapp M, Selinka H-C: Pseudovirions as specific tools for investigation of virus interactions with cells. Methods Mol Biol 2005, 295:197-212.
39. Buck CB, Thompson CD, Pang YY, Lowy DR, Schiller JT: Maturation of papillomavirus capsids. J Virol 2005, 79:2839-2846.
40. Rommel O, Dillner J, Fligge C, Bergsdorf C, Wang X, Selinka H-C, Sapp M: Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: Basis for a virus-like particle ELISA. J Med Virol 2005, 75:114-121.
41. Homepage for RasMol and OpenRasMol. Molecular graphics visualization software [http://www.rasmol.org]